Rezolute, Ersodetug, Hyperinsulinism, Congenital Hyperinsulinism, Tumor Hyperinsulinism, HI, Hypoglycemia, FDA, Pre-BLA Meeting, BLA, Biologics License Application

Rezolute Receives FDA Pre-BLA Recommendation for Ersodetug

• By cGxPwire Editor
• October 6, 2026